Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 29
2021 37
2022 52
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy in gynecological cancers.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046088 Free PMC article. Review.
Polyester materials for mRNA delivery.
Chen W, Ma Y, Liu X, Zhu D. Chen W, et al. Explor Target Antitumor Ther. 2022;3(2):117-127. doi: 10.37349/etat.2022.00075. Epub 2022 Mar 11. Explor Target Antitumor Ther. 2022. PMID: 36046844 Free PMC article. Review.
Targeted therapy of multiple myeloma.
Zhou S, Wang R. Zhou S, et al. Explor Target Antitumor Ther. 2021;2(5):465-480. doi: 10.37349/etat.2021.00057. Epub 2021 Oct 31. Explor Target Antitumor Ther. 2021. PMID: 36045700 Free PMC article. Review.
Gastrointestinal disorders as immune-related adverse events.
Balducci D, Quatraccioni C, Benedetti A, Marzioni M, Maroni L. Balducci D, et al. Explor Target Antitumor Ther. 2021;2(2):174-186. doi: 10.37349/etat.2021.00039. Epub 2021 Apr 30. Explor Target Antitumor Ther. 2021. PMID: 36046145 Free PMC article. Review.
Targeting cytoskeletal phosphorylation in cancer.
Llorente-González C, González-Rodríguez M, Vicente-Manzanares M. Llorente-González C, et al. Explor Target Antitumor Ther. 2021;2(3):292-308. doi: 10.37349/etat.2021.00047. Epub 2021 Jun 28. Explor Target Antitumor Ther. 2021. PMID: 36046434 Free PMC article. Review.
Exploring new pathways in endocrine-resistant breast cancer.
de Pinho IS, Abreu C, Gomes I, Casimiro S, Pacheco TR, de Sousa RT, Costa L. de Pinho IS, et al. Explor Target Antitumor Ther. 2022;3(3):337-361. doi: 10.37349/etat.2022.00086. Epub 2022 Jun 20. Explor Target Antitumor Ther. 2022. PMID: 36045911 Free PMC article. Review.
Proteolysis-targeting chimeras and their implications in breast cancer.
Tecalco-Cruz AC, Zepeda-Cervantes J, Ramírez-Jarquín JO, Rojas-Ochoa A. Tecalco-Cruz AC, et al. Explor Target Antitumor Ther. 2021;2(6):496-510. doi: 10.37349/etat.2021.00060. Epub 2021 Dec 31. Explor Target Antitumor Ther. 2021. PMID: 36046115 Free PMC article. Review.
Circulating biomarkers in malignant pleural mesothelioma.
Viscardi G, Di Natale D, Fasano M, Brambilla M, Lobefaro R, De Toma A, Galli G. Viscardi G, et al. Explor Target Antitumor Ther. 2020;1(6):434-451. doi: 10.37349/etat.2020.00028. Epub 2020 Dec 28. Explor Target Antitumor Ther. 2020. PMID: 36046389 Free PMC article. Review.
118 results